FDA Approves Updated COVID-19 Vaccines for Omicron KP.2 Strain Amid Concerns Over Relevance and Safety

The FDA has approved updated mRNA COVID-19 vaccines from Pfizer and Moderna targeting the Omicron variant KP.2, despite the lack of released clinical trial data. These vaccines are recommended for everyone aged 6 months and older. Critics, including several doctors and scientists, have expressed concern over the safety and necessity of these vaccines given their long-term effects and the waning protection seen in previous versions. The vaccines target strains that are no longer dominant, raising questions about their current relevance and effectiveness.

Editor’s Note: While COVID-19 has generally calmed down and the virus is evolving into milder strains, the push for new vaccines seems less urgent. The fact that these vaccines target a variant that is no longer dominant further adds to the uncertainty about their effectiveness. Let’s not ignore that the lack of released clinical trial data makes it difficult to assess their true impact, especially for a virus that now poses less of a threat to public health. Given these factors, it’s essential to critically evaluate whether these vaccines are still needed. [See also: FDA’s Push for New COVID-19 Vaccines Despite Diminished Virus Impact and Safety Concerns]

Read Original Article